Enzyme UBE2N identified as potential shield against advanced liver disease progression

Breakthrough Discovery in Liver Disease Research

Researchers at Cedars-Sinai have identified a critical enzyme called UBE2N that appears to protect the liver from damage associated with metabolic dysfunction-associated steatohepatitis (MASH), the more serious form of fatty liver disease. The discovery, published in Nature Metabolism, emerges from preclinical research suggesting that restoring normal levels of this enzyme could prevent liver disease from advancing to life-threatening stages. The findings address a significant public health challenge: an estimated 100 million Americans have metabolic dysfunction-associated steatotic liver disease (MASLD), the most common form of liver disease, with roughly 20 to 25 percent of those cases progressing to the more dangerous MASH condition characterized by inflammation, cell injury, and scarring.

How UBE2N Protects Liver Health

The enzyme UBE2N functions by removing damaged mitochondria—the cellular structures responsible for energy production—and supporting the breakdown of fat accumulation in liver cells. As liver disease advances, researchers found that UBE2N levels naturally decline, leaving the liver increasingly vulnerable to inflammatory damage. This decline appears to be a critical turning point in disease progression. By restoring UBE2N to normal levels in laboratory mice, the research team observed marked reductions in fat accumulation, inflammation, and scarring. These results demonstrate a direct protective mechanism that could form the basis for entirely new treatment approaches.

Current Treatment Limitations and Future Potential

Existing care for MASH primarily relies on lifestyle modifications and damage-limitation strategies, with relatively few pharmaceutical options available and no cure currently established. The identification of UBE2N's protective role represents a meaningful advance in understanding the underlying biology of steatotic liver disease and offers a potential new treatment target. Future research will need to determine whether enhancing this protective pathway can complement existing treatments, identify which patients would benefit most from UBE2N-boosting therapies, and develop practical therapeutic approaches for clinical use. The research was supported by multiple funding sources including the National Institutes of Health, the National Research Foundation of Korea, and the American Association for the Study of Liver Diseases.